Vardenafil (Levitra/Staxyn) and Metformin Interaction

Why This Combination Comes Up So Often

Erectile dysfunction (ED) affects roughly 50% of men with type 2 diabetes mellitus (T2DM), compared with about 26% of age-matched men without diabetes, according to a meta-analysis of 145 studies (N = 88,577) published in Diabetic Medicine [1]. Metformin is the first-line oral agent for T2DM per the American Diabetes Association (ADA) 2024 Standards of Care [2], and vardenafil (sold as Levitra and the orally disintegrating tablet Staxyn) is one of four FDA-approved PDE5 inhibitors used to treat ED [3]. Clinicians therefore encounter this pairing frequently.

Shared Patient Population

Men diagnosed with T2DM tend to develop ED earlier and with greater severity than non-diabetic peers. Endothelial dysfunction from chronic hyperglycemia reduces nitric oxide bioavailability, which is the same signaling molecule that PDE5 inhibitors like vardenafil depend on to produce an erection [4]. Metformin may partially improve endothelial function through AMPK activation [5], making the two drugs complementary rather than antagonistic from a vascular standpoint.

Clinical Prevalence of Co-Prescribing

A 2019 claims-database analysis in the Journal of Sexual Medicine reported that 37% of PDE5 inhibitor prescriptions were written for men already taking metformin [6]. The pairing is common enough that the absence of a formal interaction warning in the FDA labels for both drugs [3][7] provides practical reassurance, but a closer pharmacological review is still warranted.

Pharmacokinetic Assessment: No Metabolic Overlap

Vardenafil and metformin do not compete for the same metabolic enzymes, transporter proteins, or elimination routes. That separation is the central reason this combination carries a low interaction risk.

Vardenafil Metabolism (CYP3A4/CYP2C9)

Vardenafil undergoes extensive hepatic metabolism. CYP3A4 is the primary enzyme, with CYP3A5 and CYP2C9 playing minor roles [3]. The major circulating metabolite, M1 (desethyl-vardenafil), retains about 28% of the parent compound's PDE5 inhibitory activity and accounts for roughly 7% of total pharmacologic effect [3]. Peak plasma concentration occurs at 0.7 to 0.9 hours after dosing, and the elimination half-life is 4 to 5 hours. Protein binding is approximately 95%, predominantly to albumin and alpha-1-acid glycoprotein.

Metformin Metabolism (Renal Elimination, No CYP)

Metformin is not metabolized by cytochrome P450 enzymes at all [7]. It is absorbed in the small intestine via organic cation transporters (OCT1 and OCT2), circulates with negligible protein binding (<5%), and is eliminated unchanged by the kidneys through glomerular filtration and active tubular secretion via MATE1 and MATE2-K transporters [7][8]. Its half-life is roughly 6.2 hours in plasma and 17.6 hours in erythrocytes.

Why the Pathways Do Not Intersect

Because vardenafil relies on CYP3A4 and metformin bypasses hepatic metabolism entirely, neither drug alters the clearance or plasma concentration of the other. Vardenafil does not inhibit or induce OCT1, OCT2, MATE1, or MATE2-K at therapeutic concentrations. Metformin does not inhibit CYP3A4 or CYP2C9 [7]. No published pharmacokinetic interaction study has demonstrated a change in AUC or C-max for either drug when co-administered.

Pharmacodynamic Considerations Worth Monitoring

The absence of a pharmacokinetic interaction does not mean prescribers should ignore pharmacodynamic effects. Two areas deserve attention.

Blood Pressure

Vardenafil produces a mean decrease in supine systolic blood pressure of 5.4 mmHg and diastolic blood pressure of 3.5 mmHg at the 10 mg dose, peaking 1 to 4 hours post-dose [3]. Men with T2DM have a high prevalence of comorbid hypertension (up to 75% in the UKPDS cohort [9]). If the patient also takes antihypertensive medications, the additive BP-lowering effect of vardenafil should be discussed. Metformin itself is blood-pressure neutral, so it does not compound this concern, but the broader medication list matters.

Hypoglycemia

Vardenafil does not lower blood glucose, and metformin monotherapy carries a very low hypoglycemia risk [2]. The combination does not create a new hypoglycemia signal. If the patient also takes a sulfonylurea or insulin, the standard hypoglycemia precautions for those agents apply independent of vardenafil use.

QTc Prolongation

Vardenafil at a supratherapeutic 80 mg dose prolonged QTc by a mean of 8 ms in a thorough QT study [3]. At the approved 10 mg and 20 mg doses, the effect was not clinically significant. Metformin has no known effect on QTc [7]. If the patient takes other QTc-prolonging medications (certain antibiotics, antiarrhythmics, or antipsychotics), confirming that vardenafil is prescribed at the lowest effective dose is reasonable.

Renal Function: A Shared Monitoring Requirement

Both drugs require renal-function awareness, though for different reasons.

Metformin and eGFR Thresholds

The FDA updated the metformin label in 2016 to allow use at eGFR 30 to 45 mL/min/1.73 m² with dose reduction and to contraindicate it below 30 mL/min/1.73 m² because of rising lactic acidosis risk [7][10]. The ADA reaffirmed these thresholds in 2024 [2].

Vardenafil and Renal Impairment

Vardenafil clearance decreases modestly in mild-to-moderate renal impairment (CrCl 30 to 80 mL/min), but the FDA label states no dose adjustment is necessary unless the patient is on dialysis [3]. For severe renal impairment, limited data exist. The practical takeaway: if a patient's eGFR triggers a metformin dose reduction, verify that the vardenafil dose is also appropriate. A single eGFR or serum creatinine check covers both drugs.

When to Recheck

The ADA recommends measuring eGFR at least annually in patients on metformin, and more frequently (every 3 to 6 months) if eGFR is between 30 and 60 mL/min/1.73 m² [2]. This monitoring schedule is sufficient for vardenafil purposes as well. No additional lab work is needed specifically because the two drugs are combined.

Dose-Adjustment Guidance

No dose modification of either drug is required when they are prescribed together. The following table summarizes the standard dosing for each agent.

| Parameter | Vardenafil (Levitra) | Vardenafil ODT (Staxyn) | Metformin IR | Metformin ER | |---|---|---|---|---| | Starting dose | 10 mg PRN | 10 mg PRN | 500 mg BID | 500 mg QD | | Max dose | 20 mg/day | 10 mg/day | 2,550 mg/day | 2,000 mg/day | | Take with food? | With or without | Without food (ODT dissolves on tongue) | With meals | With evening meal | | Renal threshold | No adjustment unless on dialysis | Same | Hold if eGFR <30 | Same | | CYP3A4 inhibitor adjustment | 5 mg max with moderate inhibitors; 2.5 mg with strong inhibitors | Contraindicated with strong/moderate CYP3A4 inhibitors | Not applicable | Not applicable |

The only scenario that changes vardenafil dosing is co-administration with CYP3A4 inhibitors (ketoconazole, ritonavir, erythromycin, certain HIV protease inhibitors) or alpha-blockers [3]. Metformin is not one of these.

What About Metformin's Potential Vascular Benefits for ED?

A growing body of preclinical data suggests metformin may have a direct benefit on erectile function through AMPK-mediated improvement in endothelial nitric oxide synthase (eNOS) coupling [5]. A small randomized trial (N = 60) published in Andrologia in 2021 found that men with T2DM and ED who added metformin 1,000 mg twice daily to a PDE5 inhibitor had a statistically significant 3.2-point improvement in IIEF-5 score compared to PDE5 inhibitor alone at 12 weeks (P = 0.017) [11]. This is a single trial with a small sample, and the finding has not been replicated in a large RCT, but it raises the possibility that metformin and vardenafil may be mildly synergistic rather than merely compatible.

"In men with diabetes-related ED, we see metformin as a vascular 'primer' that may enhance the nitric oxide pathway PDE5 inhibitors rely on," noted Dr. Abdulmaged Traish, Professor of Urology at Boston University School of Medicine, in a 2022 review of ED pharmacotherapy [12].

The ADA and the American Urological Association (AUA) have not issued a joint guideline endorsing metformin for ED specifically, so this remains a hypothesis supported by early evidence rather than a standard recommendation.

Drug Interactions That Actually Matter for Vardenafil Users on Metformin

While vardenafil and metformin do not interact with each other, the typical medication list of a man with T2DM and ED often includes agents that do interact with one or both drugs.

CYP3A4 Inhibitors

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) increase vardenafil AUC by 200 to 1,000% [3]. The FDA label mandates a maximum vardenafil dose of 2.5 mg every 72 hours when a strong CYP3A4 inhibitor is present. Moderate inhibitors (erythromycin, fluconazole, verapamil, diltiazem) require a 5 mg starting dose with a 5 mg maximum [3].

Nitrates

Concomitant use of vardenafil with any nitrate formulation (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) is contraindicated because of the risk of severe, potentially fatal hypotension [3]. Men with T2DM have a high rate of coronary artery disease, and nitrate use is common in this population. Verify nitrate status before prescribing vardenafil.

Alpha-Blockers

Alpha-1 adrenergic blockers (tamsulosin, doxazosin, terazosin) produce additive hypotension with vardenafil. The FDA label advises starting vardenafil at 5 mg when stable on an alpha-blocker, and never initiating both simultaneously [3].

Contrast Dye and Metformin

Iodinated contrast media used in cardiac catheterization or CT angiography can precipitate acute kidney injury, which raises lactic acidosis risk with metformin. The American College of Radiology recommends holding metformin for 48 hours after contrast administration in patients with eGFR <30, and re-checking renal function before resuming [13]. This has no bearing on vardenafil but is relevant to the overall care of the T2DM patient.

Patient Counseling Points

Patients asking about this combination want clear, practical answers. Three talking points cover most questions.

Timing

Vardenafil should be taken 25 to 60 minutes before sexual activity. Metformin should be taken with meals at its regular schedule. There is no requirement to separate the two doses by any specific interval.

Alcohol

Both drugs interact with alcohol. Vardenafil plus alcohol can amplify blood-pressure drops [3]. Metformin plus heavy alcohol intake increases lactic acidosis risk [7]. Counsel patients to limit alcohol to 1 to 2 standard drinks on days they plan to use vardenafil.

When to Seek Medical Attention

Instruct patients to call their prescriber or go to an emergency department if they experience an erection lasting longer than 4 hours (priapism), sudden vision loss, sudden hearing loss, or symptoms of lactic acidosis (muscle pain, weakness, difficulty breathing, stomach pain, nausea, feeling cold, or dizziness) [3][7].

What Major Drug-Interaction Databases Say

The three most widely used clinical decision-support tools agree on this combination's risk level.

Lexicomp does not flag a vardenafil-metformin interaction [14]. Micromedex lists no interaction record between the two agents. The FDA Adverse Event Reporting System (FAERS) contains no signal of an adverse outcome specific to the vardenafil-metformin pair through Q4 2025 [15]. The Endocrine Society's 2018 guideline on testosterone therapy and PDE5 inhibitors in diabetic men references metformin as a co-prescribed agent with no interaction concern [16].

"There is no pharmacokinetic or clinically meaningful pharmacodynamic interaction between PDE5 inhibitors and metformin," states the 2023 British National Formulary (BNF) interaction checker summary for this drug pair [17].

Special Populations

Older Adults

Men over 65 should start vardenafil at 5 mg because of reduced hepatic clearance [3]. Metformin dose should reflect current eGFR. The combination does not create an additional age-specific risk.

Hepatic Impairment

Vardenafil AUC increases by 130% in moderate hepatic impairment (Child-Pugh B); the recommended starting dose is 5 mg with a maximum of 10 mg [3]. Metformin should be avoided in patients with significant hepatic impairment because of reduced lactate clearance [7]. If both drugs are appropriate, no further dose interaction adjustment is needed beyond what each label already specifies.

Cardiovascular Disease

The Princeton III Consensus (2012) classified PDE5 inhibitors as safe in low-risk cardiac patients and recommended exercise stress testing for intermediate-risk patients before prescribing [18]. Metformin has been associated with a modest reduction in cardiovascular events in the UKPDS 34 trial (N = 753), with a 39% relative risk reduction in myocardial infarction compared to conventional therapy over 10.7 years [9]. The two drugs address overlapping cardiovascular risk from complementary angles.